Endoscopic Therapy of Malignant Bile Duct Strictures
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients with malignant bile duct stenosis have poor prognosis and most of the patients are not good candidate for surgery at the time of diagnosis. Placement of the stent is the palliative care for these patients. However over 50% of the stents get blocked within 6-8 months. Use of the radiofrequency ablation before the stent placement may improve stent patency. Heat will be applied to the bile duct in order to open the blockage and prevent the re-growth of tissue into the stent. The investigators are looking to see how safe and feasible RFA catheter is in patient with malignant bile duct stenosis.
| Condition | Intervention |
|---|---|
|
Obstruction of Biliary Tree Biliary Tract Cancer Biliary Tract Neoplasms |
Device: Radiofrequency ablation catheter (Habib EndoHBP) |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Endoscopic Therapy of Malignant Bile Duct Strictures: A Pilot Study |
- Safety: Number of bile leak after RFA procedure [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]Determination of safety will be measured by the presence of a bile leak( bile leak will be defined by contrast cholangiography)
- Feasibility: Ease of the radiofrequency Ablation Catheter Placement [ Time Frame: 2 years ] [ Designated as safety issue: No ]Determine the feasibility of radiofrequency ablation catheter placement across malignant strictures with using a subjective scale, 0 is being impossible to place the catheter and 10 is being very easy to place the catheter.
- Effectiveness: Change from Baseline in bile duct diameter. [ Time Frame: 2 years ] [ Designated as safety issue: No ]Effectiveness will be determined by change in stricture diameter (increase or decrease) after RFA procedure.
| Estimated Enrollment: | 10 |
| Study Start Date: | February 2012 |
| Estimated Study Completion Date: | June 2014 |
| Estimated Primary Completion Date: | April 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Treatment
Radiofrequency ablation catheter
|
Device: Radiofrequency ablation catheter (Habib EndoHBP)
Catheter placement into bile duct
Other Name: Habib EndoHBP
|
Detailed Description:
As part of medical care subjects will be undergoing an endoscopic procedure (ERCP) in order to evaluate and stent a bile duct blockage. During the ECRP and just prior to the stent placement subjects will undergo the placement of a radiofrequency ablation catheter into the bile duct blockage. Heat will be applied to the bile duct in order to open the blockage and prevent the re-growth of tissue into the stent; after the radiofrequency ablation, stent will be placed. Three days after the procedure subjects will receive a phone call from the research coordinator to check any adverse or unwanted effects of the treatment. The study procedure (radiofrequency ablation) takes place over 10 minutes during ERCP. The subjects will undergo routine follow up for their medical problems. No follow up visits are required as part of the study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Documented malignant biliary obstruction requiring ERCP guided stenting
Exclusion Criteria:
- Coagulopathy (INR > 2.0 or PTT > 100 sec or platelet count < 50,000)
- Evidence of high-grade symptomatic duodenal obstruction
- Poor performance status
- Active suppurative cholangitis
- Complex stenoses will not be eligible for the trial
- Patients without access to duodenum or ampulla are not candidates for ERCP and stenting
- Candidates for a Whipple resection
- Patients who do not speak English
Contacts and Locations| United States, Massachusetts | |
| Massachusetts General Hospital | Recruiting |
| Boston, Massachusetts, United States, 02215 | |
| Contact: William R Brugge, M.D. 617-724-0578 wbrugge@partners.org | |
| Contact: Ebubekir S Daglilar, M.D 6177240462 edaglilar@partners.org | |
| Principal Investigator: William Brugge, M.D. | |
| Principal Investigator: | William R Brugge, M.D. | Massachusetts General Hospital |
More Information
Additional Information:
No publications provided
| Responsible Party: | William R. Brugge, MD, Principal Investigator, Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT01543607 History of Changes |
| Other Study ID Numbers: | 11-405 |
| Study First Received: | February 15, 2012 |
| Last Updated: | May 7, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Massachusetts General Hospital:
|
Bile duct Cholangiocarcinoma Bile duct stenosis Malignant bile duct obstruction Malignant bile duct stricture |
Radiofrequency ablation RFA Endoscopic RFA catheter EndoHPB |
Additional relevant MeSH terms:
|
Biliary Tract Neoplasms Neoplasms Cholestasis Constriction, Pathologic Digestive System Neoplasms |
Neoplasms by Site Biliary Tract Diseases Digestive System Diseases Bile Duct Diseases Pathological Conditions, Anatomical |
ClinicalTrials.gov processed this record on June 17, 2013